Statistics of Dose Reduction of the New Generation Biologics (IL-17 and IL-23 Inhibitors) in Psoriasis: a Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study, BeNeBio Study, Baseline Characterisctics